REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024. The event will take place in New York, NY, featuring a fireside chat at 8:30 a.m. ET.

Investors and interested parties can access a live webcast of the fireside chat through the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation, allowing those unable to attend the live event to catch up on the discussion.

This conference participation highlights REGENXBIO's ongoing engagement with the investment community and its commitment to sharing insights into its work in the field of genetic medicines.

News Market Reaction

-3.94%

1 alert

-3.94% News Effect

On the day this news was published, RGNX declined 3.94%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8^th Annual Genetic Medicines Conference on Monday, September 30, 2024.

Chardan's 8^th Annual Genetic Medicines Conference
Fireside Chat: Monday, September 30, 2024 at 8:30 a.m. ET
Location: New York, NY

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-chardans-8th-annual-genetic-medicines-conference-302255684.html

SOURCE REGENXBIO Inc.

FAQ

When and where is REGENXBIO (RGNX) participating in Chardan's Genetic Medicines Conference?

REGENXBIO (RGNX) is participating in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024, in New York, NY.

What time is REGENXBIO's (RGNX) fireside chat at the Chardan conference?

REGENXBIO's (RGNX) fireside chat at the Chardan conference is scheduled for 8:30 a.m. ET on Monday, September 30, 2024.

How can investors access REGENXBIO's (RGNX) presentation at the Chardan conference?

Investors can access a live webcast of REGENXBIO's (RGNX) fireside chat through the Investors section of the company's website at www.regenxbio.com.

How long will the replay of REGENXBIO's (RGNX) Chardan conference presentation be available?

An archived replay of REGENXBIO's (RGNX) presentation at the Chardan conference will be available for approximately 30 days following the event.